Stock Alert

Did you turn a 4,000% gain on your investment in one month??

If you bought Gulf BioMedical Corporation (OTC PK: GBIC) you

would have realized a 4,000% GAIN in 30 days GBIC surged from

$.05 cents to $4.00 on heavy volume.

   Ascentia BioMedical Corporation (OTC PK: ASCE) is our latest

Hot BioMedical Stock Pick!!! Ascentia BioMedical Corporation is

a microcap company which recently went public and has announced

an Anti-Cancer Compound. This company is a leading edge

research and developer of highly promising pharmaceutical

families that have already undergone significant discovery,

exploration and testing. Ascentia BioMedical is publicly traded

under the ticker symbol ASCE.

   ASCE is priced at $0.95 cents. Look for large volume

increases, followed by a sharp rise in share price. Don't Miss

Out on the next BIG move.

Current price:  $0.95 cents per share

Symbol:

Current Price

        ASCE

95 cents

6 Month Price Target                    $2.50

For More Information visit: http://www.ascentiabiomedical.com

   Ascentia BioMedical Corporation has fundamental investor

facts speculative investors should take notice of:

   * Anti-Cancer Compound: Ascentia announces option agreement

with University of Washington for Anti-Cancer Compound.

Compound has already shown repeated efficacy in blocking tumors

in a relevant, pre-clinic model of breast cancer.

   * Promising Pharmaceutical Drugs: Ascentia's core business

is to develop highly promising pharmaceutical families that

have already undergone significant discovery, exploration and

testing.

   * Price Target: Ascentia's stock is tightly held with a

small float. This share structure allows for a strong surge in

share price. 6 Month Price Target $2.50.

The Company:

   Ascentia BioMedical Corporation (ASCE) is developing and

commercializing new pharmaceutical and biomedical products for

application in a number of areas, including treatment for

asthma, arthritis, psoriasis and cancer. Initially, a majority

of these products will be secured through direct purchase or

through licensing. Initially, a majority of these products will

be secured through direct purchase or through licensing.

Ascentia is focused on therapies for cancer and diseases of

inflammation.

Company Highlights:

   ASCE Announces Option Agreement with University of

Washington for Anti-Cancer Compound: Compound already shown

repeated efficacy in blocking tumors in a relevant,

pre-clinical model of breast cancer.

   ASCE Begins Trading on OTC Pink Sheets: Ascentia BioMedical

Corporation, a leading research and developer of efficacious

pharmaceuticals, compounds and other products, announced its

common stock has begun trading under the ticker symbol ASCE.

Dr. James Clagett, President and CEO of Ascentia stated "we are

pleased to have begun trading on the Pink Sheets. It is the

first step of our goal of being listed on a national exchange.

We are excited about the prospects for our research and

products. With a growing balance sheet, an experienced

management team and a "Who's Whoâ€' for a Scientific Advisory

Board, we are well positioned for future growth.

        REASONS TO BUY THIS STOCK TODAY.

   1.) Promising Pharmaceutical Drugs: Ascentia's core business

is to develop highly promising pharmaceutical families that

have already undergone significant discovery, exploration and

testing.

   2.) Anti-Cancer Compound: Ascentia announces option

agreement with University of Washington for Anti-Cancer

Compound. Compound has already shown repeated efficacy in

blocking tumors in a relevant, pre-clinic model of breast

cancer.

   3.) Revenues: Ascentia is currently generating revenues from

contract research for third parties.

   4.) Long-term Revenues: Ascentia has a number of

opportunities to "in-license" proprietary pharmaceutical

products that will provide long-term revenue streams with

upfront milestone payments.

   5.) Advisory Board: Board comprises "Who's Who of

Scientists.

   6.) Price Target: Ascentia's stock is tightly held with a

small float. This share structure allows for a strong surge in

share price. 6 Month Price Target $2.50.

   Investment Opinion: Take advantage of current trading

levels. This is a ground floor opportunity you can't afford to

miss. At current price levels, a little bit of movement will go

a long way.

   Look for heavy volume and significant price increases in the

short term. The price of ASCE is currently trading at $0.95.

This is an inexpensive stock by anyone's standards. Don't Miss

Out.

Current Price: 0.95 cents

change subscription , please email

ocalamailman@ocalasuccess.info

with subscription in subject line

3645 ne18th Court

Ocala,Fl 34479